Development and evaluation of targeted nanomedicine for lung cancer therapy

Abstract

The application of nanotechnology to medicine is the basis for the development of nanomedicine. It is a technology in which the drug-loaded nanomedicine of 1-1000 nm exhibit strong interaction between drugs and their targets. Recent advancements in nanotechnology have contributed to the development of nanomedicine systems that enabled specific delivery of several drugs and/or macromolecules including drugs, antibodies, protein, targeting ligands and imaging agents. Anti-cancer drugs usually suffer from low solubility, rapid in-vivo degradation, poor pharmacokinetics, undesirable biodistribution and poor permeability across biological barriers. During chemotherapy, large doses are recommended for treatment, which may induce adverse effects on normal cells and the surrounding healthy organs. Thus, the objective of this study was to design and develop targeted delivery systems with the aim of restricting high dose administration and reducing the dose-related adverse side effects and also the frequency of dosing. newlineChitosan is a nontoxic, semicrystalline, biodegradable and biocompatible linear polysaccharide of randomly distributed N-acetyl glucosamine and glucosamine units. The amino as well as carboxyl groups of the chitosan molecule usually form a hydrogen bond by lipoprotein interaction with the cell membrane, bringing out an ideal adhesive effect. Docetaxel is a second-generation taxane derived from the needles of the European yew tree. Unlike paclitaxel, docetaxel exhibits linear pharmacokinetics and, due to differences in drug efflux, is retained intracellularly for a longer period. D-and#945;- tocopherol glycol 1000 succinate (TPGS) is a surfactant used for pharmaceutical dosage form preparations. It is a water-soluble derivative of natural Vitamin E, which is formed by esterification of vitamin E succinate with PEG.